Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 35
Region Europe at a glance
Diabetes market by value and
Novo Nordisk market share
Diabetes trend in population
Million
Population with diabetes
Diabetes growth rate
50
8%
NN Insulin MS
NN OAD MS
bDKK
80
40
60
39
30
36
30
20
20
40
40
20
10
N/A
0
0
2000
2017
2045
Aug
2013
Novo Nordisk reported sales
NN GLP-1 MS
First nine months of
2018
Sales
(mDKK)
YTD
growth²
100%
Long-acting insulin³
3,162
9%
Premix insulin4
20.4%¹
1,270 (10%)
80%
Fast-acting insulin5
3,365
4%
Human insulin
1,184
60%
(10%)
4.5%¹ Insulin
Total insulin
8,981
1%
40%
GLP-16
2,784
10%
Other diabetes care?
432
(4%)
10.4%¹
OAD
20%
Diabetes care
12,197
3%
Obesity (SaxendaⓇ)
145
121%
0%
Aug
2018
Biopharm³
3,743
(2%)
Total
16,085
2%
Europe Population 2018: ~0.6 billion people and diabetes prevalence
~8.8%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share for Insulin as of Aug 2018: Sanofi 35%
and Eli Lilly 18%
Competitor value market share for GLP-1 as of Aug 2018: Eli Lilly 32%
and AstraZeneca 11%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Aug, 2018 value figures
2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018
3 Comprises Tresiba®, XultophyⓇ and Levemir®; 4 Comprises NovoMixⓇ
and RyzodegⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ; 6 Comprises
VictozaⓇ and Ozempic®; 7 Comprises Novo Norm® and needles;
8Comprises primarily NovoSeven®, NovoEight® NovoThirteen®, Refixia®,
Norditropin®, Vagifem® and ActivelleⓇView entire presentation